Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breast implants

This article was originally published in The Gray Sheet

Executive Summary

Federal government is cleared to pursue reimbursement for Medicare payments that went to treat injuries allegedly suffered by silicone breast implant claimants involved in a 1995 class action settlement valued at $4.2 bil. The Department of Justice filed suit in Birmingham district court in March 2000 to recover its expenditures; however, the court later dismissed the complaint, in part due to the government's inability to identify specific patients. A Sept. 15 ruling by the U.S. Court of Appeals for the 11th Circuit allows the case to proceed against defendants Baxter, Bristol-Myers Squibb, 3M and Union Carbide, but remands the case back to the district court for resolution (1"The Gray Sheet" April 10, 2000, In Brief)...

You may also be interested in...



Breast Implants

U.S. Department of Justice files suit in Birmingham federal court March 31 to recover federal expenditures in treating injuries incurred by silicon breast implant claimants, following a breakdown in negotiations with implant manufacturers over the government's claims. The suit, which names Baxter, Bristol-Meyers Squibb, 3M and Union Carbide as defendants, seeks to enjoin disbursement of settlement funds under Medicare secondary payer laws and the Medical Care Recovery Act until the government's rights are resolved

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel